Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 05 - 31 tags : Drug save search
FSD PHARMA FILES INVESTIGATIONAL NEW DRUG APPLICATION (“IND”) WITH FDA AND HEALTH CANADA FOR PHASE-2 TRIAL OF FSD-201 FOR AN INFLAMMATORY DISORDER
Published: 2022-05-31 (Crawled : 07:00) - fsdpharma.com
HUGE | News | $0.461 0.46% 580K
|
Process Industries
|
| O: -1.09%
H: 1.1%
C: -1.92%
fsd-201 fda pharma drug canada health application trial phase 2
Lexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure
Published: 2022-05-31 (Crawled : 21:00) - biospace.com/
LXRX | $1.54 -3.75% 300K
|
Health Technology
|
| O: 1.72%
H: 5.65%
C: 0.0%
treatment drug heart application
Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate Cancer
Published: 2022-05-31 (Crawled : 18:00) - biospace.com/
JANX | $46.61 -3.32% 16K
|
Professional, Scientific, and T...
|
| O: 0.6%
H: 0.25%
C: -5.6%
janx007 fda clearance drug application therapeutics cancer prostate cancer
Stealth BioTherapeutics Receives Orphan Drug Designation from the European Medicines Agency for Elamipretide for the Treatment of Myopathic Mitochondrial DNA Depletion Syndrome
Published: 2022-05-31 (Crawled : 17:00) - biospace.com/
MITO | $0.32 0.25%
|
Health Technology
|
| O: 6.08%
H: 40.84%
C: 19.56%
treatment elamipretide designation drug dna
At 9.10% CAGR, Therapeutic Drug Monitoring Market Size is Expected to Reach USD 2854.83 Billion by 2027 Says Zion Market Research | Global Therapeutic Drug Monitoring Industry Trends, Share, Analysis & Forecast Report
Published: 2022-05-31 (Crawled : 15:00) - prnewswire.com
DHR | $246.81 -1.44% 110K
|
Health Technology
|
| O: -1.0%
H: 0.3%
C: -0.0%
XGN | $1.38 2.6K
|
Health Services
|
| O: -1.17%
H: 2.17%
C: -1.38%
drug research report expected market
FSD Pharma Files Investigational New Drug Application (“IND”) with FDA and Health Canada for Phase-2 Trial of FSD-201 for an Inflammatory disorder and Provides Corporate Updates
Published: 2022-05-31 (Crawled : 13:00) - biospace.com/
HUGE | News | $0.461 0.46% 580K
|
Process Industries
|
| O: -1.09%
H: 1.1%
C: -1.92%
fsd-201 fda pharma drug canada health application trial phase 2
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-101 for the Treatment of Hematologic Malignancies
Published: 2022-05-31 (Crawled : 12:00) - biospace.com/
TCRX | News 3 d | $7.38 1.65% 1.76% 0
|
Professional, Scientific, and T...
|
| O: -1.23%
H: 4.05%
C: -0.31%
tsc-101 treatment fda clearance drug application therapeutics
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
CSSE 4 | $0.299 96.32% 7M
|
Consumer Services
BRFH 4 | $1.99 80.91% 13M
|
Manufacturing
LICN | $1.0 78.57% 3.3M
|
BOF | $1.915 63.68% 620K
|
MTC | $3.62 61.61% 790K
|
Technology Services
AMST | $3.13 56.5% 500K
|
Technology Services
ACON | $0.3595 24.83% 3.5M
|
n/a
ILAG | $0.669 23.89% 13M
|
CDTX | News | $14.57 18.55% 330K
|
Health Technology
MNY | $2.11 17.22% 180K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.